Company intelligence / Profile preview
Q32 Bio
Waltham, Massachusetts, United Statesq32bio.com ↗
- Ownership
- Public · QTTB
- Employees
- ~43
- Development stage
- Other
01
Overview
Currently advancing bempikibart (ADX-914) in Phase 2 trials for alopecia areata with FDA Fast Track designation granted in April 2025. The company has completed a Phase 1 clinical study of ADX-097 in healthy volunteers and is preparing to initiate Phase 2 trials.
- Therapeutic areas
- ImmunologyDermatologyNephrology
- Modalities
- Monoclonal antibodies (mAbs)Protein therapeutics
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Previously partnered with Horizon Therapeutics (2022)
04
Financials
- Market cap
- $263.5M
- Total revenue
- $53.7M
- Enterprise value
- $-16.6M
Beyond the preview
Go deeper on Q32 Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Q32 Bio.